Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier P Gisbert

Showing results (521-530 of 568) with videos related to

Pageof 57
Sort By:
Nature Medicine|January 12, 2026
Interpretable inflammation landscape of circulating immune cellsLaura Jiménez-Gracia, Davide Maspero, Sergio Aguilar-Fernández, et al.
Gut|January 2, 2023
Empirical rescue treatment of <i>Helicobacter pylori</i> infection in third and subsequent lines: 8-year experience in 2144 patients from the European Registry on <i>H. pylori</i> management (Hp-EuReg)Diego Burgos-Santamaría, Olga P Nyssen, Antonio Gasbarrini, et al.
United European Gastroenterology Journal|April 30, 2024
Role of compliance in Helicobacter pylori eradication treatment: Results of the European Registry on H. pylori managementJose M Huguet, Luis Ferrer-Barceló, Patrícia Suárez, et al.
Postgraduate Medical Journal|June 24, 2024
Influence of familial forms of inflammatory bowel disease on the use of immunosuppressants, biological agents, and surgery in the era of biological therapies. Results from the ENEIDA projectCarlos González-Muñoza, Margalida Calafat, Javier P Gisbert, et al.
Antibiotics (Basel, Switzerland)|September 28, 2023
Analysis of Clinical Phenotypes through Machine Learning of First-Line <i>H. pylori</i> Treatment in Europe during the Period 2013-2022: Data from the European Registry on <i>H. pylori</i> Management (Hp-EuReg)Olga P Nyssen, Pietro Pratesi, Miguel A Spínola, et al.
Antibiotics (Basel, Switzerland)|December 30, 2020
European Registry on <i>Helicobacter pylori</i> Management: Effectiveness of First and Second-Line Treatment in SpainMaría Caldas, Ángeles Pérez-Aisa, Manuel Castro-Fernández, et al.
The American Journal of Gastroenterology|April 12, 2021
Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg)Olga P Nyssen, Angeles Perez-Aisa, Bojan Tepes, et al.
Pharmaceutics|May 25, 2024
Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDACelia Gómez-Labrador, Elena Ricart, Marisa Iborra, et al.
Scientific Reports|October 11, 2023
Comparison of the management of Helicobacter pylori infection between the older and younger European populationsPaulius Jonaitis, Olga P Nyssen, Ilaria Maria Saracino, et al.
Journal of Clinical Medicine|July 14, 2023
<i>Helicobacter pylori</i> Diagnostic Tests Used in Europe: Results of over 34,000 Patients from the European Registry on <i>Helicobacter pylori</i> ManagementNatalia García-Morales, Ángeles Pérez-Aísa, Giulia Fiorini, et al.
Pageof 57

Showing results (521-530 of 568) with videos related to

Sort By:
Pageof 57
Nature Medicine|January 12, 2026
Interpretable inflammation landscape of circulating immune cellsLaura Jiménez-Gracia, Davide Maspero, Sergio Aguilar-Fernández, et al.
Gut|January 2, 2023
Empirical rescue treatment of <i>Helicobacter pylori</i> infection in third and subsequent lines: 8-year experience in 2144 patients from the European Registry on <i>H. pylori</i> management (Hp-EuReg)Diego Burgos-Santamaría, Olga P Nyssen, Antonio Gasbarrini, et al.
United European Gastroenterology Journal|April 30, 2024
Role of compliance in Helicobacter pylori eradication treatment: Results of the European Registry on H. pylori managementJose M Huguet, Luis Ferrer-Barceló, Patrícia Suárez, et al.
Postgraduate Medical Journal|June 24, 2024
Influence of familial forms of inflammatory bowel disease on the use of immunosuppressants, biological agents, and surgery in the era of biological therapies. Results from the ENEIDA projectCarlos González-Muñoza, Margalida Calafat, Javier P Gisbert, et al.
Antibiotics (Basel, Switzerland)|September 28, 2023
Analysis of Clinical Phenotypes through Machine Learning of First-Line <i>H. pylori</i> Treatment in Europe during the Period 2013-2022: Data from the European Registry on <i>H. pylori</i> Management (Hp-EuReg)Olga P Nyssen, Pietro Pratesi, Miguel A Spínola, et al.
Antibiotics (Basel, Switzerland)|December 30, 2020
European Registry on <i>Helicobacter pylori</i> Management: Effectiveness of First and Second-Line Treatment in SpainMaría Caldas, Ángeles Pérez-Aisa, Manuel Castro-Fernández, et al.
The American Journal of Gastroenterology|April 12, 2021
Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg)Olga P Nyssen, Angeles Perez-Aisa, Bojan Tepes, et al.
Pharmaceutics|May 25, 2024
Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDACelia Gómez-Labrador, Elena Ricart, Marisa Iborra, et al.
Scientific Reports|October 11, 2023
Comparison of the management of Helicobacter pylori infection between the older and younger European populationsPaulius Jonaitis, Olga P Nyssen, Ilaria Maria Saracino, et al.
Journal of Clinical Medicine|July 14, 2023
<i>Helicobacter pylori</i> Diagnostic Tests Used in Europe: Results of over 34,000 Patients from the European Registry on <i>Helicobacter pylori</i> ManagementNatalia García-Morales, Ángeles Pérez-Aísa, Giulia Fiorini, et al.
Pageof 57